Biotechnology

ACROBiosystems expands custom GMP-grade protein services to drive CGT development and commercialization

TOKYO, June 7, 2023 /PRNewswire/ -- Cell and gene therapy (CGT) is a cutting-edge therapy that combats cancer by bolstering the immune system through stem cell infusions or modified immune cells. However, manufacturing cell therapies isno easy feat. To support the commercialization of cell thera...

2023-06-07 16:05 2735

ACROBiosystems expands custom GMP-grade protein services to drive CGT development and commercialization

NEWARK, Del., June 7, 2023 /PRNewswire/ -- Cell and gene therapy (CGT) is a cutting-edge therapy that combats cancer by bolstering the immune system through stem cell infusions or modified immune cells. However, manufacturing cell therapies is no easy feat. Cell therapy products have a higher R&D...

2023-06-07 14:57 2544

Gencurix Announces Clinical Research Results At ASCO Demonstrating Outstanding Performance of GenesWellBCT Compared to Global Best-Selling Test, OncotypeDX

SEOUL, South Korea, June 7, 2023 /PRNewswire/ -- Gencurix an nounced the release of clinical research results comparing the accuracy of its breast cancer prognostic test, GenesWellBCT, with OncotypeDX, the globally top-s...

2023-06-07 12:29 2771

BetaLife wins Cytiva's first BioChallenge Competition in Southeast Asia

* BetaLife wins top prize with its potential to provide regenerative medicines to patients with severe diabetes inSoutheast Asia. * Cytiva's BioChallenge aims to support the innovation of biotech startups. Singapore, June 7, 2023 /PRNewswire/ -- Cytiva recognizes the talent, resource and scal...

2023-06-07 12:00 2739

Nona Biosciences Appoints Steve Arkinstall, D. Phil., as Chief Scientific Advisor

CAMBRIDGE, Mass., June 6, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to I™), today announced the appointment of Steve Arkinstall, D.Ph...

2023-06-07 09:00 2569

ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023

SHENZHEN, China, June 6, 2023 /PRNewswire/ -- ImmVira submitted four abstracts covering latest results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) and MVR-T3011 IV (intravenous injection) in both U.S. andChina with all selected to be published (1 chosen for poster dis...

2023-06-07 08:00 2416

LiveSpo represents Vietnam to announce the world's first spore probiotics in nasal spray form at the BIO International Convention

BOSTON, June 6, 2023 /PRNewswire/ -- LiveSpo is the first representative from Vietnam to participate in the BIO International Convention, an exhibition showcasing breakthrough biotechnology solutions, held inBoston, USA. This demonstrates the remarkable development of the Vietnamese pharmaceutica...

2023-06-06 19:40 2612

2023 ASCO | Multi-center Data for Combination Study of GenFleet's GFH018 (TGF-β R1 inhibitor) with Anti-PD-1 Antibody Demonstrates Significant Potential to Enhance Efficacy of Immune Checkpoint Inhibitors among ICI-naïve Patients

SHANGHAI and CHICAGO, June 6, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today published the latest results from the phase Ib/II study of GFH018 (TGF-β R1 inhibitor) with toripalimab(anti-PD-1 ...

2023-06-06 19:00 2012

Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025

- Marking the first phase of the company's second Bio Campus, Plant 5 is expected to have shortest construction timeline - Samsung Biologics will maintain the world's largest biomanufacturing capacity at 784,000 liters upon completion of the newest plant - Key features of Plant 5 include seamless ...

2023-06-06 19:00 2228

Acepodia Secures $100 Million Series D Financing to Advance

First-In-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform Series D led by Digital Mobile Venture with participation from additional existing investors Funds will support expansion and progress of oncology pipeline, including ACE1831 and ACE2016, antibody armed allogeneic gamma ...

2023-06-06 18:00 1913

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

SUZHOU, China and ROCKVILLE, Md., June 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that for the second consecutive year, it has release...

2023-06-06 12:20 3227

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

SUZHOU, China and ROCKVILLE, Md,, June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released preliminary results from a Phas...

2023-06-06 10:45 2209

Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting

* As of November 10, 2022, 26 patients with HER2-positive unresectable or metastatic solid tumors (other than breast cancer and gastric/gastroesophageal junction cancer) were enrolled, 92.3% of whom had received ≥2L prior systemic therapy. The objective response rate (ORR) was 53.8% with 6.8 mo...

2023-06-06 09:06 2431

Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, June 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2023-06-06 08:00 4393

Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries

* Subjects in Bunionectomy Study Dosed  * Data Presented at American Society for Pharmacology and Experimental Therapeutics Shows Similar Ropivacaine Pharmacokinetic Curves From CPL-01 Across Multiple Surgeries; Minimal Variability as Compared to Liposomal Bupivacaine SAN DIEGO, June 5, 2023 ...

2023-06-06 00:00 2706

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company,  announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Cl...

2023-06-05 21:26 2902

RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name

The "B" marker is removed from the Company's stock short name YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a fully-integrated commercial-stage biotechnology company, successfully obtained approval fro...

2023-06-05 21:17 3680

Fresh2 Group Ltd. Announces US$4.4 Million Private Placement

NEW YORK, June 5, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commer...

2023-06-05 21:00 3049

Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure

Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with symptomatic heart failure who have iron deficiency ST. GALLEN, Switzerland, June 5, 2023 /PRNewswire/ -- CSL...

2023-06-05 21:00 3136

Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing

News Summary: * Integration of Sartorius' process scale multi-column chromatography with Waters' process analytical technology to provide robust analytical data for downstream biomanufacturing of mAbs, recombinant proteins, vaccines, and other biologics. * Integrated solution to deliver vita...

2023-06-05 20:00 3049
1 ... 99100101102103104105 ... 307

Week's Top Stories